Trospium chloride: the European experience.
The primary pharmacological therapy for overactive bladder syndrome is muscarinic receptor antagonists. Muscarinic receptor blockade is effective in decreasing the symptoms of urinary urgency and urgency incontinence, but can be associated with troublesome complications, such as dry mouth, blurred vision, constipation and CNS side effects. Trospium chloride, an antimuscarinic medication, has been available in Europe for > 20 years and has recently been approved by the FDA for the treatment of overactive bladder. Trospium chloride is a quaternary amine that is minimally metabolised, not highly protein bound and, importantly, has not been demonstrated to cross the unaltered blood-brain barrier in healthy volunteers. Some characteristics of this unique antimuscarinic agent and the European experience with trospium chloride are reviewed in this article.
Madersbacher
Helmut
H
Neuro-Urology Unit, University-Klinik Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria. helmut.madersbacher@tilak.at
Rovner
Eric
E
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001561:Benzilates; D002648:Child; D005060:Europe; D005260:Female; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009662:Nortropanes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D043585:Receptor, Muscarinic M2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D043587:Receptor, Muscarinic M3 / Q000037:antagonists & inhibitors / Q000378:metabolism; D001743:Urinary Bladder / Q000187:drug effects / Q000378:metabolism; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000378:metabolism
D001561:Benzilates; D018727:Muscarinic Antagonists; D009662:Nortropanes; D043585:Receptor, Muscarinic M2; D043587:Receptor, Muscarinic M3; C003330:trospium chloride